A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This proposed trial will investigate the combination of amrubicin and carboplatin in the
first-line treatment of patients with extensive-stage small cell lung cancer (ES- SCLC).
Since myelosuppression is the most common toxicity produced by this drug combination,
pegfilgrastim will be administered with each treatment cycle. This trial will be the first
clinical trial to evaluate a combination of amrubicin and carboplatin in the first-line
treatment of ES SCLC in a U.S. population.